We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Urology

Journal Scan / Research · May 19, 2022

Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide in Patients With Advanced Prostate Cancer

Journal of the National Cancer Institute


Additional Info

Journal of the National Cancer Institute
Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer
J. Natl. Cancer Inst 2022 Apr 13;[EPub Ahead of Print], LY Lai, MK Oerline, MEV Caram, PA Tsao, SR Kaufman, BK Hollenbeck, VB Shahinian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading